Equities

Structure Therapeutics Inc

GPCR:NMQ

Structure Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)38.02
  • Today's Change-0.33 / -0.86%
  • Shares traded412.57k
  • 1 Year change-45.99%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

  • Revenue in USD (TTM)0.00
  • Net income in USD-100.44m
  • Incorporated2019
  • Employees136.00
  • Location
    Structure Therapeutics Inc611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO 94080United StatesUSA
  • Websitehttps://structuretx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Disc Medicine Inc0.00-91.00m1.93bn74.00--3.95-----3.66-3.660.0016.450.00----0.00-20.35---21.06--------------0.00-------63.22------
Nurix Therapeutics Inc56.42m-176.98m1.94bn284.00--4.87--34.32-2.91-2.910.92225.620.1373----198,676.10-43.07-33.01-52.51-39.66-----313.65-260.65----0.00--99.3115.5020.19--39.42--
Mirum Pharmaceuticals Inc264.38m-109.16m2.00bn294.00--8.73--7.58-2.40-2.405.814.810.47885.065.521,001,424.00-19.77-38.93-23.38-44.8872.27---41.29-190.713.09--0.573--141.85---20.45--21.81--
Spyre Therapeutics Inc0.00-185.98m2.01bn50.00--9.20-----15.42-15.420.007.370.00----0.00-54.73-101.87-87.47-118.83-------2,949.59----0.00---61.96-25.61-304.21------
MannKind Corp248.37m11.74m2.02bn414.00204.77--116.648.130.03590.03590.834-0.82260.6562.859.71599,937.203.10-26.074.05-37.8071.2959.684.73-57.613.761.861.89--99.4248.1786.34--160.47--
Recursion Pharmaceuticals Inc65.18m-377.75m2.04bn500.00--3.87--31.22-1.53-1.530.26311.830.096--24.06130,368.00-55.66---65.45--35.07---579.51------0.0519--11.88---36.99------
Fortrea Holdings Inc2.88bn-228.20m2.11bn16.00k--1.44--0.732-2.56-3.2332.3016.330.7262--3.48159,794.40-5.76---7.11--17.17---7.93-----0.33740.4348--0.4167---101.76------
Neumora Therapeutics Inc0.00-274.18m2.17bn108.00--5.68-----1.66-1.660.002.380.00----0.00-71.73---76.67--------------0.00-------80.23------
Structure Therapeutics Inc (ADR)0.00-100.44m2.17bn136.00--2.36-----2.24-2.240.0016.100.00----0.00-17.07---17.64--------------0.00-------69.62------
Azenta Inc658.62m-156.38m2.19bn3.30k--1.13--3.33-2.82-2.8111.7339.500.24433.083.49188,176.30-5.80-0.5934-6.27-0.672539.7843.08-23.74-2.174.21--0.00--19.731.04-14.15--25.26--
Beam Therapeutics Inc349.64m-143.59m2.24bn436.00--2.82--6.41-1.72-1.724.279.580.284----801,933.50-11.67-24.54-13.84-29.26-----41.07-211.96----0.00--520.01--54.16--20.78--
Longboard Pharmaceuticals Inc0.00-64.74m2.33bn50.00--7.89-----2.16-2.160.007.580.00----0.00-34.15---36.32--------------0.00-------23.84------
Akero Therapeutics Inc0.00-204.18m2.39bn61.00--2.99-----3.41-3.410.0011.530.00----0.00-26.71-37.73-27.66-40.13------------0.042-------35.46------
Wave Life Sciences Ltd110.50m-73.74m2.39bn266.00------21.66-0.5796-0.57960.92750.03590.5036----415,413.50-33.49-56.98-117.16-102.38-----66.50-353.20----0.00--3,005.1051.0464.46---35.44--
Data as of Nov 08 2024. Currency figures normalised to Structure Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

56.49%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 30 Jun 20247.32m12.80%
Fidelity Management & Research Co. LLCas of 30 Jun 20245.37m9.39%
Janus Henderson Investors US LLCas of 30 Jun 20243.31m5.78%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20243.13m5.48%
Driehaus Capital Management LLCas of 30 Jun 20242.58m4.51%
BVF Partners LPas of 30 Jun 20242.49m4.35%
Federated Global Investment Management Corp.as of 30 Jun 20242.41m4.21%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20242.31m4.05%
RA Capital Management LPas of 30 Jun 20241.90m3.32%
Capital Research & Management Co. (International Investors)as of 30 Jun 20241.50m2.62%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.